GlassScriptPhysician profile
Bryan Lee Chan
NPI 1518699982
$894.72
in general payments reported to CMS, 2019-2025
17 companies · $651 in 2025
The $651 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $244 · 2025: $651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $894.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $243.65 | 2024 | Veklury |
| E.R. Squibb & Sons, L.L.C. | $74.97 | 2025 | Opdualag, Opdivo |
| Beone Medicines USA, INC. | $71.95 | 2025 | Brukinsa, Tevimbra |
| Janssen Biotech, INC. | $70.44 | 2025 | Erleada, Balversa |
| Incyte Corporation | $53.71 | 2025 | Jakafi, Zynyz, Monjuvi |
| Celgene Corporation | $50.63 | 2025 | Reblozyl |
| Agios Pharmaceuticals, INC. | $44.40 | 2025 | Pyrukynd |
| Alexion Pharmaceuticals, INC. | $41.91 | 2025 | Ultomiris |
| Syndax Pharmaceuticals, INC. | $31.71 | 2025 | |
| Pharmaessentia USA Corporation | $30.76 | 2025 | Besremi |
| Deciphera Pharmaceuticals INC. | $29.45 | 2025 | Romvimza, Qinlock |
| Daiichi Sankyo INC. | $29.00 | 2025 | Datroway |
| Coherus Oncology, INC. | $27.04 | 2025 | Loqtorzi |
| Pfizer INC. | $26.63 | 2025 | |
| Springworks Therapeutics, INC. | $25.85 | 2025 | Ogsiveo |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $22.10 | 2025 | Dovato |
| Kyowa Kirin, INC. | $20.52 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.